Related Experiment Videos
Intravascular microaggregation and in vitro platelet aggregation in coronary artery disease
Insights
In coronary artery disease patients, platelets in aortic and pulmonary artery blood show increased in vitro aggregation. However, increased in vivo microaggregates are found in coronary sinus blood, regardless of disease presence.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biomedical Engineering
Background:
- Microaggregation and platelet responsiveness are critical in cardiovascular health.
- Understanding these processes in coronary artery disease (CAD) is essential for diagnosis and treatment.
- Blood sampling from different circulatory points provides insights into localized aggregation dynamics.
Purpose of the Study:
- To investigate in vivo and in vitro microaggregation in coronary artery disease patients.
- To compare microaggregate formation and platelet reactivity in blood from the aorta, pulmonary artery, and coronary sinus.
- To determine if coronary artery disease influences these aggregation parameters.
Main Methods:
- Blood samples were collected from the aorta, pulmonary artery, and coronary sinus during cardiac catheterization.
- An electronic particle size analyzer quantified microaggregates (13-81 μm).
- Platelet responsiveness to adenosine diphosphate (ADP) was assessed in vitro.
Main Results:
- Coronary artery disease patients showed larger in vitro ADP-induced aggregate sizes in aortic and pulmonary artery blood.
- In vivo microaggregate volume was significantly greater in coronary sinus blood compared to aorta and pulmonary artery, irrespective of CAD.
- In vitro ADP-induced aggregate volume and size were smaller in coronary sinus blood versus pulmonary artery blood.
Conclusions:
- Increased in vivo microaggregate volume in coronary sinus blood is independent of coronary artery disease.
- Coronary artery disease patients exhibit heightened platelet reactivity to in vitro aggregatory agents in aortic and pulmonary artery samples.
- Findings suggest localized microaggregation differences and altered platelet function in CAD.
Abstract:
To investigate in vivo and in vitro microaggregation in coronary artery disease, we obtained blood samples from the coronary sinus (CS), pulmonary artery (PA), and aorta (AO) in patients undergoing cardiac catheterization. An electronic particle size analyzer was used to quantify microaggregates 13 to 81 mu in diameter in blood. In the first group of 58 patients, preformed circulating microaggregates and platelet responsiveness to ADP were assessed in AO and PA blood only. The coronary artery disease patients did not have significantly higher volumes of preformed in vivo aggregates in either AO or PA blood. However, the mean aggregate size in response to 0.2 microM ADP in vitro was larger in both AO and PA blood in patients with coronary disease [12.4 +/- 0.9 vs. 9.4 +/- 1.4 X 10(3) mu3 (AO); 12.5 +/- 0.9 vs. 8.3 +/- 0.7 0.7 X 10(3) mu3 (PA)]. In a second group of 46 patients, CS, AO and PA samples were compared using the same methods. The volume of microaggregates preformed in vivo was significantly greater in CS blood than in PA or AO blood in patients with and without coronary disease. The volume and mean size of aggregates induced by ADP in vitro were smaller in CS blood compared to PA. In conclusion, the volume of in vivo microaggregates is increased in CS blood, independent of coronary disease, but significant volumes are not found in PA or AO blood. Patients with coronary disease have more reactive platelets to in vitro aggregatory agents in AO and PA samples of similar hematocrit.